Role of First Trimester Screening Biochemical Markers to Predict Hypertensive Pregnancy Disorders and SGA Neonates-A Narrative Review

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2023 Sep 9

PMID 37685488

Authors

Wojciech Gorczewski

Joanna Gorecka

Magdalena Massalska-Wolska

Magdalena Staskiewicz

Dariusz Borowski

Hubert Huras

Magda Rybak-Krzyszkowska

Affiliations

Soon will be listed here.

Abstract

Early recognition of high-risk pregnancies through biochemical markers may promote antenatal surveillance, resulting in improved pregnancy outcomes. The goal of this study is to evaluate the possibilities of using biochemical markers during the first trimester of pregnancy in the prediction of hypertensive pregnancy disorders (HPD) and the delivery of small-for-gestational-age (SGA) neonates. A comprehensive search was conducted on key databases, including PubMed, Scopus, and Web of Science, for articles relating to the use of biochemical markers in the prediction of HPD and SGA. The findings show that changes in the levels of biomarkers in the early pregnancy phases could be an important indicator of adverse pregnancy outcomes. The literature shows that low PAPP-A (pregnancy-associated plasma protein A) and PlGF (placental growth factor) levels, low alkaline phosphatase (AP), higher sFlt-1 (soluble fms-like Tyrosine Kinase-1) levels, higher AFP (alfa fetoprotein) levels, and elevated levels of inflammatory markers such as β-HGC (free beta human chorionic gonadotropin), interferon-gamma (INF-γ), and tumor necrosis factor-α (TNF-α) may be associated with risks including the onset of HPD, fetal growth restriction (FGR), and delivery of SGA neonates. Comparatively, PAPP-A and PlGF appear to be the most important biochemical markers for the prediction of SGA and HPD.

References

Genc S, Ozer H, Emeklioglu C, Cingillioglu B, Sahin O, Akturk E . Relationship between extreme values of first trimester maternal pregnancy associated plasma Protein-A, free-β-human chorionic gonadotropin, nuchal translucency and adverse pregnancy outcomes. Taiwan J Obstet Gynecol. 2022; 61(3):433-440. DOI: 10.1016/j.tjog.2022.02.043. View

Erkamp J, Jaddoe V, Duijts L, Reiss I, Mulders A, Steegers E . Population screening for gestational hypertensive disorders using maternal, fetal and placental characteristics: A population-based prospective cohort study. Prenat Diagn. 2020; 40(6):746-757. PMC: 7317936. DOI: 10.1002/pd.5683. View

Shaarawy M . Plasma endothelin-1 and mean arterial pressure in the prediction of pre-eclampsia. Int J Gynaecol Obstet. 2000; 68(2):105-11. DOI: 10.1016/s0020-7292(99)00180-0. View

Liu S, Li W, Zhang J, Qi L, Dong Y, Fu L . Clinical value of flow-mediated dilatation of brachial artery in hypertensive disorders complicating pregnancy. Clin Hemorheol Microcirc. 2022; 82(3):265-274. DOI: 10.3233/CH-221533. View

Lees C, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F . ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020; 56(2):298-312. DOI: 10.1002/uog.22134. View

Hendrix M, Bons J, Snellings R, Bekers O, van Kuijk S, Spaanderman M . Can Fetal Growth Velocity and First Trimester Maternal Biomarkers Improve the Prediction of Small-for-Gestational Age and Adverse Neonatal Outcome?. Fetal Diagn Ther. 2019; 46(4):274-284. PMC: 6878734. DOI: 10.1159/000499580. View

Kornacki J, Gutaj P, Kalantarova A, Sibiak R, Jankowski M, Wender-Ozegowska E . Endothelial Dysfunction in Pregnancy Complications. Biomedicines. 2021; 9(12). PMC: 8698592. DOI: 10.3390/biomedicines9121756. View

Borowski D, Pietryga M, Basta P, Cnota W, Czuba B, Dubiel M . Practice guidelines of the Polish Society of Gynecologists and Obstetricians - Ultrasound Section for ultrasound screening in uncomplicated pregnancy - 2020. Ginekol Pol. 2020; 91(8):490-501. DOI: 10.5603/GP.2020.0110. View

Berhe A, Ilesanmi A, Aimakhu C, Mulugeta A . Effect of pregnancy induced hypertension on adverse perinatal outcomes in Tigray regional state, Ethiopia: a prospective cohort study. BMC Pregnancy Childbirth. 2020; 20(1):7. PMC: 6938605. DOI: 10.1186/s12884-019-2708-6. View

10.

Regitz-Zagrosek V, Roos-Hesselink J, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M . 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34):3165-3241. DOI: 10.1093/eurheartj/ehy340. View

11.

Magee L, Smith G, Bloch C, Cote A, Jain V, Nerenberg K . Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022; 44(5):547-571.e1. DOI: 10.1016/j.jogc.2022.03.002. View

12.

Zhang J, Han L, Li W, Chen Q, Lei J, Long M . Early prediction of preeclampsia and small-for-gestational-age via multi-marker model in Chinese pregnancies: a prospective screening study. BMC Pregnancy Childbirth. 2019; 19(1):304. PMC: 6700825. DOI: 10.1186/s12884-019-2455-8. View

13.

. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002; 77(1):67-75. View

14.

Bao X, Huo G, Li L, Cao X, Liu Y, Lakshmipriya T . Coordinated Dispersion and Aggregation of Gold Nanorod in Aptamer-Mediated Gestational Hypertension Analysis. J Anal Methods Chem. 2019; 2019:5676159. PMC: 6881590. DOI: 10.1155/2019/5676159. View

15.

Elazab R, Alkhiary M, Bedairi M, Wageh A . Simultaneous use of Tumor Necrosis Factor, Lipid Profile, and β-hCG As Markers of Severity of Preeclampsia. J Obstet Gynaecol India. 2022; 72(Suppl 1):83-88. PMC: 9343506. DOI: 10.1007/s13224-021-01556-0. View

16.

Poon L, Nicolaides K . First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014; 34(7):618-27. DOI: 10.1002/pd.4397. View

17.

Honarjoo M, Zarean E, Tarrahi M, Kohan S . Role of pregnancy-associated plasma protein A (PAPP-A) and human-derived chorionic gonadotrophic hormone (free β-hCG) serum levels as a marker in predicting of Small for gestational age (SGA): A cohort study. J Res Med Sci. 2022; 26:104. PMC: 8765518. DOI: 10.4103/jrms.JRMS_560_20. View

18.

Shah D, Khalil R . Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol. 2015; 95(4):211-26. PMC: 4449835. DOI: 10.1016/j.bcp.2015.04.012. View

19.

Duan Z, Li C, Leung W, Wu J, Wang M, Ying C . Alterations of Several Serum Parameters Are Associated with Preeclampsia and May Be Potential Markers for the Assessment of PE Severity. Dis Markers. 2020; 2020:7815214. PMC: 6983284. DOI: 10.1155/2020/7815214. View

20.

Lowe S, Bowyer L, Lust K, McMahon L, Morton M, North R . SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015; 55(5):e1-29. DOI: 10.1111/ajo.12399. View